ASPASIA MANTA¹, SPYRIDON KAZANAS², STEFANOS KARAMAROUDIS³, HELEN GOGAS², DIMITRIOS C. ZIOGAS^2,*

Oncology Research, Vol.30, No.5, pp. 211-219, 2022, DOI:10.32604/or.2022.026913 - 03 February 2023

Abstract Epigenetic mechanisms, such as DNA methylation and histone modifications (e.g., acetylation and deacetylation), are strongly implicated in the carcinogenesis of various malignancies. During transcription, the expression and functionality of coding gene products are altered following the histone acetylation and deacetylation. These processes are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. HDAC inhibitors (HDACis) have been developed as promising therapeutic agents, to limit exposure to traditional and toxic chemotherapies and offer more alternatives for some specific malignant diseases with limited options. Mechanistically, these agents affect many intracellular pathways, including cell cycle arrest, apoptosis… More >

Vivian Adamski^*, Anne Dorothée Schmitt^*, Charlotte Flüh^*, Michael Synowitz^*, Kirsten Hattermann^†1, Janka Held-Feindt^*1

Oncology Research, Vol.25, No.3, pp. 341-353, 2017, DOI:10.3727/096504016X14737243054982

Abstract Gliomas are the most common primary brain tumors. The most malignant form, the glioblastoma multiforme (GBM; WHO IV), is characterized by an invasive phenotype, which enables the tumor cells to infiltrate into adjacent brain tissue. When investigating GBM migration and invasion properties in vitro, in most cases GBM cell lines were analyzed. Comprehensive investigations focusing on progression-dependent characteristics of migration processes using fresh human glioma samples of different malignancy grades do not exist. Thus, we isolated fast-migrating tumor cells from fresh human glioma samples of different malignancy grades (astrocytomas WHO grade II, grade III, GBM,… More >

Marco Locatelli¹, Leonardo Boiocchi^1,2, Stefano Ferrero², Filippo Martinelli Boneschi³, Mario Zavanone^1,4, Samantha Pesce⁵, Paola Allavena⁵, Sergio Maria Gaini^1,4, Lorenzo Bello^1,4, Alberto Mantovani^5,6

European Cytokine Network, Vol.21, No.1, pp. 27-33, 2010, DOI:10.1684/ecn.2009.0184

Abstract The chemokine receptor CX3CR1 and its cognate ligand CX3CL1 (also known as fractalkine), are involved in central nervous system pathophysiology, in particular, in the cross-talk between neurons and micro-glia. It was therefore important to investigate the expression of CX3CR1 in gliomas, the most frequently occur-ring, malignant brain tumors. In a consecutive series of 70 patients with primary, central nervous glial tumors, CX3CR1 was highly expressed in tumor cells as assessed by RT-PCR mRNA and protein levels, and by immu-nohistochemistry, while the corresponding normal cells were negative. Receptor immuno-positivity did not correlate with histology, grade, chromosomal More >